drugset / Trial / NCT02935309

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

NCT02935309

NaSingle-groupOpen-labelTreatment

Summary

This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and what the best dosage is.

Timeline

Start
2016-10-14
Primary completion
2019-10-11
Completion
2020-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 850 mg/m2
Subject Lenvatinib Small molecule 10 mg Oral
Subject Lenvatinib Small molecule 14 mg Oral
Subject Lenvatinib Small molecule 20 mg Oral
Subject Lenvatinib Small molecule 24 mg Oral

Indications